106. Cryopyrin-associated periodic syndrome Clinical trials / Disease details
Clinical trials : 42 / Drugs : 24 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01045772 (ClinicalTrials.gov) | January 2009 | 7/1/2010 | Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) | A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS) | Muckle-Wells Syndrome;Schnitzler Syndrome | Drug: rilonacept | Charite University, Berlin, Germany | NULL | Completed | 18 Years | N/A | Both | 10 | Phase 2 | Germany |
| 2 | EUCTR2006-004290-97-DE (EUCTR) | 19/12/2008 | 17/10/2006 | A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1 | A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1 | The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis. | Trade Name: Rilonacept | Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy | NULL | Not Recruiting | Female: yes Male: yes | Germany | ||||
| 3 | NCT00288704 (ClinicalTrials.gov) | December 2005 | 6/2/2006 | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) | IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs | Familial Cold Autoinflammatory Syndrome (FCAS);Familial Cold Urticaria;Muckle-Wells Syndrome (MWS);Genetic Diseases, Inborn | Drug: rilonacept 160 mg;Drug: Placebo | Regeneron Pharmaceuticals | NULL | Completed | 7 Years | N/A | All | 104 | Phase 3 | United States |